Show simple item record

dc.contributor.authorEslam, M
dc.contributor.authorMcLeod, D
dc.contributor.authorKelaeng, KS
dc.contributor.authorMangia, A
dc.contributor.authorBerg, T
dc.contributor.authorThabet, K
dc.contributor.authorIrving, WL
dc.contributor.authorDore, GJ
dc.contributor.authorSheridan, David
dc.contributor.authorGrønbæk, H
dc.contributor.authorAbate, ML
dc.contributor.authorHartmann, R
dc.contributor.authorBugianesi, E
dc.contributor.authorSpengler, U
dc.contributor.authorRojas, A
dc.contributor.authorBooth, DR
dc.contributor.authorWeltman, M
dc.contributor.authorMollison, L
dc.contributor.authorCheng, W
dc.contributor.authorRiordan, S
dc.contributor.authorMahajan, H
dc.contributor.authorFischer, J
dc.contributor.authorNattermann, J
dc.contributor.authorDouglas, MW
dc.contributor.authorLiddle, C
dc.contributor.authorPowell, E
dc.contributor.authorRomero-Gomez, M
dc.contributor.authorGeorge, J
dc.contributor.authorMetwally, M
dc.contributor.authorWhite, R
dc.contributor.authorGallego-Duran, R
dc.contributor.authorLeung, R
dc.contributor.authorMahajan, N
dc.contributor.authorBassendine, M
dc.contributor.authorRahme, A
dc.contributor.authorRosso, C
dc.contributor.authorMezzabotta, L
dc.contributor.authorMalik, B
dc.contributor.authorMatthews, G
dc.contributor.authorAsimakopoulos, A
dc.contributor.authorApplegate, T
dc.contributor.authorGrebely, J
dc.contributor.authorFragomeli, V
dc.contributor.authorJonsson, JR
dc.contributor.authorSantoro, R
dc.date.accessioned2017-04-28T11:48:51Z
dc.date.available2017-04-28T11:48:51Z
dc.date.issued2017-04-10
dc.identifier.issn1061-4036
dc.identifier.issn1546-1718
dc.identifier.urihttp://hdl.handle.net/10026.1/9163
dc.description.abstract

Genetic variation in the IFNL3-IFNL4 (interferon-λ3-interferon-λ4) region is associated with hepatic inflammation and fibrosis. Whether IFN-λ3 or IFN-λ4 protein drives this association is not known. We demonstrate that hepatic inflammation, fibrosis stage, fibrosis progression rate, hepatic infiltration of immune cells, IFN-λ3 expression, and serum sCD163 levels (a marker of activated macrophages) are greater in individuals with the IFNL3-IFNL4 risk haplotype that does not produce IFN-λ4, but produces IFN-λ3. No difference in these features was observed according to genotype at rs117648444, which encodes a substitution at position 70 of the IFN-λ4 protein and reduces IFN-λ4 activity, or between patients encoding functionally defective IFN-λ4 (IFN-λ4-Ser70) and those encoding fully active IFN-λ4-Pro70. The two proposed functional variants (rs368234815 and rs4803217) were not superior to the discovery SNP rs12979860 with respect to liver inflammation or fibrosis phenotype. IFN-λ3 rather than IFN-λ4 likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

dc.format.extent795-800
dc.format.mediumPrint-Electronic
dc.languageen
dc.language.isoen
dc.publisherSpringer Science and Business Media LLC
dc.subjectFibrosis
dc.subjectGene Frequency
dc.subjectGenotype
dc.subjectHaplotypes
dc.subjectHepacivirus
dc.subjectHepatitis C
dc.subjectHumans
dc.subjectInflammation
dc.subjectInterferons
dc.subjectInterleukins
dc.subjectLinkage Disequilibrium
dc.subjectLiver
dc.subjectLogistic Models
dc.subjectMultivariate Analysis
dc.subjectPolymorphism, Single Nucleotide
dc.subjectReverse Transcriptase Polymerase Chain Reaction
dc.titleIFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000400051400020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue5
plymouth.volume49
plymouth.publication-statusPublished
plymouth.journalNature Genetics
dc.identifier.doi10.1038/ng.3836
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeUnited States
dcterms.dateAccepted2017-03-13
dc.rights.embargodate2017-10-10
dc.identifier.eissn1546-1718
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1038/ng.3836
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-04-10
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV